Cargando…
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy with BRAF and MEK inhibitors is associated with significant long-term treatment benefit in patients with BRAF V600-mutated melanom...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758899/ https://www.ncbi.nlm.nih.gov/pubmed/29148538 http://dx.doi.org/10.1038/modpathol.2017.104 |